The Access to Advanced Health Institute reports encouraging results of first-in-human trial of its temperature-stable tuberculosis vaccine candidate
2023-03-06
(Press-News.org) The Access to Advanced Health Institute (AAHI) published results of a Phase 1 clinical trial demonstrating the safety and immune responses in a new vaccine against tuberculosis (TB), the world’s second deadliest infectious disease (NCT03722472). AAHI’s TB vaccine combines several proteins from Mycobacterium tuberculosis (Mtb), the bacterium that causes TB, into a fusion protein (“ID93”) with a proprietary immune-stimulating adjuvant (“GLA-SE”) in a freeze-dried formulation that can be stored at elevated temperatures (nearly 100 degrees Fahrenheit) for months. The novel single-vial presentation of this freeze-dried TB vaccine candidate elicited a stronger immune response than administration of the same vaccine using separate vials of antigen and liquid adjuvant formulation. AAHI’s single-vial TB vaccine candidate represents significant progress in global efforts to combat TB.
The trial evaluated the safety, tolerability, and immunogenicity of AAHI’s thermostable, freeze-dried single-vial ID93 + GLA-SE vaccine candidate compared to the previous iteration of the vaccine—a two-vial presentation that had demonstrated promising safety and immunogenicity in Phase 2 clinical testing. Importantly, the thermostable single-vial presentation induced higher levels of antibodies than the two-vial presentation, while retaining the vaccine candidate’s ability to activate “helper T cells” that recruit additional immune cells for a stronger immune response. The trial enrolled 48 participants who were to receive two vaccine doses administered intramuscularly 56 days apart, after which the researchers observed the cellular immune response profile thought to be favorable for protection against Mtb.
“Adjuvanted subunit vaccines have re-energized the field of TB vaccine development. This study represents the first temperature-stable adjuvant-containing subunit TB vaccine candidate to be evaluated in the clinic,” says Christopher Fox, PhD, Senior Vice President of Formulations and Principal Investigator of the contract awarded by the National Institutes of Health (NIH) that funded the trial. “An effective thermostable TB vaccine would not only be better suited to reach areas of the world most burdened by the disease, but it would also mitigate costs and reduce wastage associated with more stringent cold-chain storage requirements.”
TB spreads when infected people expel the bacterium into the air; TB claimed 1.6 million lives and infected 10.6 million people in 2021. The World Health Organization estimates that nearly 2 billion people across the globe are infected with Mtb. The COVID-19 pandemic impeded global progress toward control of TB by diverting resources from TB prevention and treatment efforts. Available resources were dedicated to combatting the COVID-19 pandemic, which also led to a reduction in TB case reporting, resulting in a later detection and treatment of TB and creating the opportunity for additional community transmission of infection. If proved effective in larger clinical trials, AAHI’s vaccine candidate will be a unique asset in the arsenal of control tools to reverse the resurgence of TB.
Additional studies will be needed to scaleup manufacturing and establish that the vaccine candidate will protect populations in low-resource communities most burdened by TB, such as in Southeast Asia and Sub-Saharan Africa, that struggle to maintain even simple refrigeration for vaccine transport and storage. By reducing the need for coldchain, AAHI’s TB vaccine candidate may significantly advance the global fight against TB.
“Equitable access to vaccines has been significantly impeded by cold-chain requirements and, as observed with COVID-19, no one is safe until everyone is safe,” explains Corey Casper, MD, MPH, Chief Executive Officer at AAHI. “The development of a safe and immunogenic temperature-stable TB vaccine is a major achievement towards our mission of bringing vaccines to people who most need them, regardless of geography.”
The research and development of the thermostable single-vial TB vaccine candidate received support from multiple partners: NIH/National Institute of Allergy and Infectious Diseases (NIAID), Saint Louis University, Lyophilization Technology Inc., Advanced Biosciences Laboratories, DF/Net Research, and the Center for Biocatalysis and Bioprocessing at the University of Iowa.
The project described here is supported by NIAID contract HHSN272201400041C. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.
####
AAHI is a nonprofit biotech research institute located in Seattle, Washington, that combines the high-quality science of an academic research organization with the product-development capabilities of a biotech company to help combat some of the world’s deadliest diseases, including COVID-19, cancer, fungal and parasitic infections, and other non-communicable diseases. For nearly three decades, AAHI, previously known as the Infectious Disease Research Institute, has focused on creating immune-enhancing technologies that improve the body’s natural response to disease. Through collaborations, AAHI brings innovation from the lab to the clinic to the people, furthering AAHI’s mission to bring together the best experts, technologies, and platforms to create accessible, high-quality products and solutions. AAHI is working to build a world in which every person has access to tools that harness their immune system and allow them to live a healthy life free of illness and disease. For more information, go to AAHI.org or follow us on LinkedIn.
Media Contacts:
Casey Benadof
Media@aahi.org
(206) 960-1479
END
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
2023-03-06
A global team of researchers has created an algorithmic tool that can identify existing drugs in order to combat future pandemics. The work, reported in the Cell Press journal Heliyon, offers the possibility of responding more quickly to public-health crises.
“There is no silver bullet to defeat the Covid pandemic as it takes us over a public-health roller-coaster of deaths and devastation,” explains Naomi Maria, an immunologist, a visiting scientist at New York University’s Courant Institute of Mathematical Sciences, and the paper’s lead author. “However, using this AI tool, coupled with in vitro data and other resources, we’ve ...
2023-03-06
Study’s findings may lead to more personalized follow-up care for patients.
New research indicates that for patients with breast cancer, the cancer’s stage and receptor status can help clinicians predict whether and when cancer might recur after initial treatment. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
For the study, Heather Neuman, MD, MS, of the University of Wisconsin, and her colleagues analyzed data on 8,007 patients with stage I–III breast cancer who participated in nine clinical trials from 1997–2013 ...
2023-03-06
In the earliest days of human flight, before the invention of the first radio beacons and ground-based electronic systems, and modern GPS, pilots commonly navigated by following roads and railways – striking linear landscape elements at ground level that guide towards a destination of interest.
Enter the honeybee. A century of research has shown that honeybees are navigators par excellence. They can navigate by their sense of smell, the sun, the sky’s pattern of polarized light, vertical landmarks that stand out from the panorama, and possibly the Earth’s magnetic field. They are also clever learners, able to recognize associations between disparate ...
2023-03-06
PITTSBURGH, March 6, 2023 — The monthly opioid overdose death (ODD) rate fell by 30% in Pennsylvania counties that implemented a novel community-focused strategy developed by University of Pittsburgh researchers, according to a new study published today in the Journal of Studies on Alcohol and Drugs.
By analyzing counties that did or didn’t implement the Pennsylvania Opioid Overdose Reduction Technical Assistance Center (ORTAC) strategy over time, the researchers estimate that this cost-effective, community-led approach prevented 1,818 opioid-related deaths over two years.
“I ...
2023-03-06
Conifers are generally better than broadleaved trees at purifying air from pollutants. But deciduous tree may be better at capturing particle-bound pollution. A new study led by the University of Gothenburg shows that the best trees for air purification depend on the type of pollutant involved.
Trees and other greenery in cities provide many benefits that are important for the well-being of residents. Leaves and needles on trees filter air pollutants and reduce exposure to hazardous substances in the air. But which trees purify the air most effectively? Researchers from the University ...
2023-03-06
Scientists in Japan have revealed a chemical compound that could be used for the treatment of various autoimmune diseases like multiple sclerosis and rheumatoid arthritis. These diseases occur when the body’s immune response goes wiry. The immune system, which normally attacks pathogens and infections, instead attacks healthy cells and tissues. For the millions of people who suffer from autoimmune diseases worldwide, the result can be debilitating—rheumatoid arthritis causes excessive joint pain, while multiple sclerosis can disable one’s brain and spinal cord function.
“The key to the development of autoimmune ...
2023-03-06
Promoting physical activity and other behavioural support can help people wanting to reduce their smoking to quit in the short-term.
However, after nine months, physical activity delivers no noticeable benefits – compared with offering no additional support – in the rates of people stopping smoking, according to the findings of a major national study.
The Trial of physical Activity and Reduction of Smoking (TARS) study, led by the University of Plymouth with funding from the National Institute for Health and Care Research, took place across four cities – Plymouth, Nottingham, Oxford and ...
2023-03-06
A total of 1,261,990 people will die from cancer in 2023 in the EU (EU-27). A further 172,314 people will die from the disease in the UK, according to new research published in the leading cancer journal Annals of Oncology [1] today (Monday).
Researchers led by Carlo La Vecchia (MD), a professor at the University of Milan (Italy), estimate there will be a 6.5% fall in cancer death rates in men and a 3.7% fall in women between 2018 and 2023.
They predict that death rates from the ten most common cancers will continue to fall in most European countries in 2023, although the numbers of people dying will go up ...
2023-03-06
Globally, activated sludge treats the majority of urban wastewaters; yet it is one of the most complex biological processes used. It is a sophisticated microbial process fraught with operational problems leading to occasional failures in achieving required effluent quality standards. With the increasing problem of partially treated and raw sewage entering rivers and estuaries, the pressure on the process to cope with ever increasing volumes of wastewater has never been so great.
With increasing volumes of dilute wastewater entering treatment plants the high variability in hydraulic and organic ...
2023-03-06
Cell membranes are barriers that maintain cellular homeostasis, and the intracellular delivery of biologically functional molecules, including peptides, proteins, and nucleic acids to manipulate cellular functions. Conventional intracellular uptake processes require high concentrations of biofunctional molecules with low permeability to pass through the cell membrane. This results in low drug activity because the probability of the biofunctional molecules entering target cells and their organelles is low. In addition, many drugs damage healthy cells as well as the cells that are supposed to target due to poor selectivity, making ...
LAST 30 PRESS RELEASES:
[Press-News.org] The Access to Advanced Health Institute reports encouraging results of first-in-human trial of its temperature-stable tuberculosis vaccine candidate
